EUVIMEDEUVIMED entdecken
Leitlinie

As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline

Sandhya Khurana iD, Alex R Jenkins iD, Helen K Reddel iD, Praveen Akuthota iD, Rodolfo M Alpizar-Rivas iD, Juan Carlos Cardet iD, Melody G Duvall iD, O'Neil J Green iD, Tina V Hartert iD, Elliot Israel iD, Nizar N Jarjour iD, Christopher M Kearney iD und 12 weitere

American Journal of Respiratory and Critical Care Medicine · 03.11.2026

DOI: 10.1093/ajrccm/aamag577 ↗

Kurz gefasst

Leitlinie in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 03.11.2026. Verfasst von Sandhya Khurana und 23 weiteren Autor:innen. Beteiligte Einrichtung: University of Rochester.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhaled corticosteroid (ICS)-containing reliever therapy has demonstrated efficacy in improving asthma outcomes when compared to short-acting beta2-agonists (SABA) alone but remains underutilized. The purpose of this guideline is to provide recommendations surrounding the use of combination ICS-formoterol or ICS+SABA (in combination or separate inhalers) as reliever therapy across the asthma severity spectrum in adolescents and adults.

Methods

The American Thoracic Society clinical practice guideline panel evaluated six research questions in the PICO format addressing the use of ICS-containing reliever therapy across National Asthma Education and Prevention Program (NAEPP) asthma treatment steps 1-5. The methodology team conducted systematic literature reviews and GRADE assessments, which the panel utilized to inform the recommendations for each specific PICO and overall. Recommendations In patients at NAEPP steps 1 and 2, the panel made strong recommendations for the use of as-needed-only ICS-SABA or ICS-formoterol over SABA-only therapy, and conditional recommendations over scheduled ICS + as-needed SABA. In patients at NAEPP steps 3-5, the taskforce made a strong recommendation for the use of maintenance-and-reliever therapy (MART) with ICS-formoterol over scheduled ICS-LABA plus as-needed SABA. In patients at NAEPP steps 3-5 who are using scheduled maintenance ICS-LABA, the panel made a conditional recommendation for use of ICS+SABA reliever over SABA reliever. In considering these recommendations, the panel valued the importance of preventing severe exacerbations and considered the risk of SABA-only treatment, as well as ICS and systemic corticosteroid (SCS) exposure.

Conclusions

This clinical practice guideline, informed by systematic reviews and GRADE-based appraisals of PICO-framed evidence, makes these evidence-based recommendations for the safe and effective use of ICS-containing reliever therapy in asthma.

Schlagwörter

Stichwörter der Autor:innen

anti-inflammatory reliever (AIR)as-needed ICS+SABAas-needed ICS-formoterolasthmamaintenance and reliever therapy (MART)

Autor:innen und Institutionen

  • University of Rochester.
  • Petauri Evidence, United Kingdom.
  • Woolcock Institute of Medical Research, Macquarie University, Sydney, Australia.
  • University of California San Diego.
  • Wake Forest School of Medicine.
  • University of South Florida.

ORCID-Profile: Sandhya Khurana, Alex R Jenkins, Helen K Reddel, Praveen Akuthota, Rodolfo M Alpizar-Rivas, Juan Carlos Cardet, Melody G Duvall, O'Neil J Green, Tina V Hartert, Elliot Israel, Nizar N Jarjour, Christopher M Kearney, Shandra L Knight, Ashley J Losier, Njira L Lugogo, Arjun Mohan, Paul M O'Byrne, Richard P Ramonell, Sunita Sharma, Neha Solanki, Charlie Strange, Mark A Aronica

Zitieren

APA

Khurana, S., Jenkins, A. R., Reddel, H. K., Akuthota, P., Alpizar-Rivas, R. M., Cardet, J. C., Duvall, M. G., Green, O. J., Hartert, T. V., Israel, E., Jarjour, N. N., Kearney, C. M., Knight, S. L., Losier, A. J., Lugogo, N. L., Mohan, A., O'Byrne, P. M., Ramonell, R. P., Sharma, S., …, & American Thoracic Society Assembly on Allergy, Immunology and Inflammation (2026). As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1093/ajrccm/aamag577

Vancouver

Khurana S, Jenkins AR, Reddel HK, Akuthota P, Alpizar-Rivas RM, Cardet JC, et al. As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline. American Journal of Respiratory and Critical Care Medicine. 2026. doi:10.1093/ajrccm/aamag577

BibTeX
@article{Khurana2026,
  author = {Khurana, Sandhya and Jenkins, Alex R and Reddel, Helen K and Akuthota, Praveen and Alpizar-Rivas, Rodolfo M and Cardet, Juan Carlos and Duvall, Melody G and Green, O'Neil J and Hartert, Tina V and Israel, Elliot and Jarjour, Nizar N and Kearney, Christopher M and Knight, Shandra L and Losier, Ashley J and Lugogo, Njira L and Mohan, Arjun and O'Byrne, Paul M and Ramonell, Richard P and Sharma, Sunita and Solanki, Neha and Strange, Charlie and Stevenson, Glen G and Aronica, Mark A and American Thoracic Society Assembly on Allergy, Immunology and Inflammation, American Thoracic Society Assembly on Allergy, Immunology and Inflammation},
  title = {As-needed inhaled corticosteroids in asthma: an Official American Thoracic Society clinical practice guideline},
  journal = {American Journal of Respiratory and Critical Care Medicine},
  year = {2026},
  doi = {10.1093/ajrccm/aamag577}
}
Kostenlos starten →